CNS To Present at the Life Sciences Investor Forum

Rhea-AI Summary

CNS Pharmaceuticals, focused on treatments for brain cancers, announced that CEO John Climaco will present at the Life Sciences Investor Forum on June 25, 2020, from 12:30 PM to 1:00 PM ET. This online event will allow investors to ask questions in real-time, with an archived webcast available later. CNS is advancing Berubicin, its lead drug candidate, for treating GBM, a fatal brain cancer, and expects to initiate a Phase 2 trial later this year. Investors can pre-register for the event here.

HOUSTON, June 23, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc., (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the Life Sciences Investor Forum being held virtually on June 25^th, 2020 at 12:30pm ET.

Details of the presentation are below:

Event:	Life Sciences Investor Forum
Date:	June 25th, 2020
Time:	12:30 – 1:00 PM ET
Link:	https://www.lifesciencesinvestorforum.com/events/event-details/agenda

This will be an interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register for the event using the following link: https://www.lifesciencesinvestorforum.com/login-registration.

Learn more about the event at www.lifesciencesinvestorforum.com.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006.  In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has been shown in preclinical studies to be 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.  For more information, please visit www.cnspharma.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements include, without limitation, the Company's ability to initiate a Phase II trial evaluating the effect of Berubicin on patients with glioblastoma later this year. These statements relate to future events, future expectations, plans and prospects. Although CNS believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-to-present-at-the-life-sciences-investor-forum-301081618.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

What is CNS Pharmaceuticals presenting at the Life Sciences Investor Forum on June 25, 2020?

CNS Pharmaceuticals will present their developments in treatments for brain cancers, focusing on their lead drug candidate, Berubicin.

What time does CNS Pharmaceuticals' presentation start on June 25, 2020?

The presentation starts at 12:30 PM ET.

How can investors participate in the Life Sciences Investor Forum?

Investors can participate by registering for the event and can ask questions in real-time.

What is the significance of the Phase 2 trial for Berubicin announced by CNS Pharmaceuticals?

The Phase 2 trial aims to evaluate the effectiveness of Berubicin in treating GBM, a highly aggressive brain cancer.

Where can I find more information about the Life Sciences Investor Forum?

More information can be found at the official event website: www.lifesciencesinvestorforum.com.